EUROFINS SCIENTIFIC

Eurofins Scientific’s Europe Investor Day on Oct 23 reveals strong earnings, share‑purchase activity, and a future outlook that reinforces its leadership in analytical testing.

Eurofins Scientific’s Paris session surge shows strong investor confidence, driven by insider buying and robust life‑sciences testing, boosting its market standing.

Eurofins Scientific SE’s Q3 2026 earnings: 4‑6% revenue growth, 11% margin, automation‑driven efficiency, and a resilient pharma‑lab portfolio poised for future expansion.